

## REMARKS

Upon entry of the foregoing Amendment, Claims 1, 3-5, 8, 12 and 13 will remain pending in the application. Claims 2, 6, 7, 9-11 and 14 22 have been canceled. These changes do not introduce new matter, and their entry is respectfully requested.

In the Final Office Action dated December 7, 2009, the Examiner sets forth a number of grounds for rejection. These grounds are addressed individually and in detail below.

### **Claim Objection**

Claim 6 stands objected to as being of improper dependent form for failing to further limit the subject matter of a previous claim. Claim 6 has been canceled and this objection is now moot.

### **Claim Rejections Under 35 U.S.C. § 103(a)**

Claim 6 stands rejected under 35 U.S.C. § 103(a) as being obvious over Wolff et al. (hereinafter “Wolff”) (Blood, Vol 102, No.11, page 404b) in view of Dave et al. (hereinafter “Dave”) (U.S. Patent No. 6,491,923) and Stehle et al. (hereinafter “Stehle”) (Anti-Cancer Drugs, Vol.8, pages 677-685) for the reasons set forth on pages 2-3 of the Office Action; Claims 15 and 20 stand rejected under 35 U.S.C. § 103(a) as being obvious over Sutton et al. (hereinafter “Sutton”) (U.S. Patent No. 5,993,805) in view of Sinkule et al. (hereinafter “Sinkule EP Application”) (European Patent Application No. EP0282057) or Low et al. (hereinafter “Low”) (U.S. Patent No. 5,688,488), for the reasons set forth on pages 3-6 of the Office Action. Applicant respectfully traverses this rejection.

In order to expedite the prosecution, Applicant has canceled Claims 6, 15 and 20. These grounds of the rejection are now moot.

**Allowable Subject Matter**

Applicant would like to thank the Examiner for the indication that Claims 1, 3-5, 8, 12 and 13 are allowed.


## **CONCLUSION**

All of the stated grounds of rejection have been properly traversed, accommodated, or rendered moot. Applicant therefore respectfully requests that the Examiner reconsider all presently outstanding rejections and that they be withdrawn. It is believed that a full and complete response has been made to the outstanding Office Action and, as such, the present application is in condition for allowance.

If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to contact Applicant's counsel, Ping Wang, M.D. (Reg. No. 48,328), at 202.842.0217.

Respectfully submitted,

MORRIS, MANNING & MARTIN, LLP



---

Ping Wang, M.D.  
Registration No. 48,328

1333 H Street, N.W.  
Suite 820  
Washington, D.C. 20005  
Telephone No. 202.842.0217  
Facsimile No. 202.408.5146